ArticleBlood2009
Prox1 physically and functionally interacts with COUP-TFII to specify lymphatic endothelial cell fate.
Article in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 164 citations in OpenAlex.
- Bidirectional crosstalk between obesity and the lymphatic system: a novel pathway in obesity pathogenesis and treatment.International journal of obesity (2005) · 2026Review
- Endothelial VEGFR2 insufficiency promotes the transition of lymphatic to hematopoietic transcriptional programs.Angiogenesis · 2026Article
- Immunohistochemical investigation of the transcription factor PROX1 emphasizing on neuroendocrine neoplasms.Medical molecular morphology · 2026Article
- Beyond Drainage: How Lymphatic Vessels Instruct Immune Cell Fate.Journal of inflammation research · 2026Review
- Molecular Mechanisms and Therapeutic Strategies Targeting Cardiac Lymphangiogenesis in Heart Failure.Cardiovascular toxicology · 2025Review
- Lymph Node-Targeted Cyclosporine A Alleviates Myocarditis in Lupus Mice by Inhibiting CD68+ Macrophage-Driven Lymphangiogenesis.Materials today (Kidlington, England) · 2025Article
- Extracellular vesicle-mediated transmission of circPDLIM5 promotes lymphatic metastasis in prostate cancer.Journal of experimental & clinical cancer research : CR · 2025Article
- Characteristics and advances in signaling pathways, cellular communication, cell junctions, and oxidative stress in lymphedema.Frontiers in cell and developmental biology · 2025Review
- Article
- Piezo1 regulates meningeal lymphatic vessel drainage and alleviates excessive CSF accumulation.Nature neuroscience · 2024Article
- Lymphatic vessel: origin, heterogeneity, biological functions, and therapeutic targets.Signal transduction and targeted therapy · 2024Review
- Direct male development in chromosomally ZZ zebrafish.Frontiers in cell and developmental biology · 2024Article
- Prox1 Suppresses the Proliferation of Breast Cancer Cells via Direct Inhibition of c-Myc Gene Expression.Cells · 2023Article
- Isolation and short-term culturing of primary lymphatic endothelial cells from collecting lymphatics: A techniques study.Microcirculation (New York, N.Y. : 1994) · 2023Article
- PROX1-mediated epigenetic silencing ofInternational journal of biological sciences · 2023Article
- An NKX-COUP-TFII morphogenetic code directs mucosal endothelial addressin expression.Nature communications · 2022Article
- Role of Transcriptional and Epigenetic Regulation in Lymphatic Endothelial Cell Development.Cells · 2022Review
- Mechanical forces in lymphatic vessel development: Focus on transcriptional regulation.Frontiers in physiology · 2022Review
- Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies.Frontiers in pharmacology · 2022Review
- CCM3 Loss-Induced Lymphatic Defect Is Mediated by the Augmented VEGFR3-ERK1/2 Signaling.Arteriosclerosis, thrombosis, and vascular biology · 2021Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Specification of endothelial cell (EC) fate during vascular development is controlled by distinct key regulators. While Notch plays an essential role in induction of arterial phenotypes, COUP-TFII is required to maintain the venous EC identity. Homeodomain transcription factor Prox1 functions to reprogram venous ECs to lymphatic endothelial cells (LECs). Here, we report that the venous EC fate regulator COUP-TFII is expressed in LECs throughout development and physically interacts with Prox1 to form a stable complex in various cell types including LECs. We found that COUP-TFII functions as a coregulator of Prox1 to control several lineage-specific genes including VEGFR-3, FGFR-3, and neuropilin-1 and is required along with Prox1 to maintain LEC phenotype. Together, we propose that the physical and functional interactions of the 2 proteins constitute an essential part in the program specifying LEC fate and may provide the molecular basis for the hypothesis of venous EC identity being the prerequisite for LEC specification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.